AAAAAA

   
Results: 1-8 |
Results: 8
THYMIDYLATE SYNTHASE (TS) LEVELS IN COLORECTAL-CANCER AS MEASURED USING A NEW POLYCLONAL ANTIBODY - CORRELATION WITH CLINICAL OUTCOME
Authors: MAROUN JA JONKER D ROBERTSON S HAQQANI A BIRNBOIM HC
Citation: Ja. Maroun et al., THYMIDYLATE SYNTHASE (TS) LEVELS IN COLORECTAL-CANCER AS MEASURED USING A NEW POLYCLONAL ANTIBODY - CORRELATION WITH CLINICAL OUTCOME, Annals of oncology, 9, 1998, pp. 236-236
PROGRESS OF CLINICAL ONCOLOGY GUIDELINES DEVELOPMENT USING THE PRACTICE GUIDELINES DEVELOPMENT CYCLE - THE ROLE OF PRACTITIONER FEEDBACK
Authors: BROWMAN GP NEWMAN TE MOHIDE EA GRAHAM ID LEVINE MN PRITCHARD KI EVANS WK MAROUN JA HODSON DI CAREY MS COWAN DH
Citation: Gp. Browman et al., PROGRESS OF CLINICAL ONCOLOGY GUIDELINES DEVELOPMENT USING THE PRACTICE GUIDELINES DEVELOPMENT CYCLE - THE ROLE OF PRACTITIONER FEEDBACK, Journal of clinical oncology, 16(3), 1998, pp. 1226-1231
PHASE-I CLINICAL-STUDY OF DIDEMNIN-B - A NATIONAL-CANCER-INSTITUTE OFCANADA CLINICAL-TRIALS GROUP-STUDY
Authors: MAROUN JA STEWART D VERMA S EISENHAUER E
Citation: Ja. Maroun et al., PHASE-I CLINICAL-STUDY OF DIDEMNIN-B - A NATIONAL-CANCER-INSTITUTE OFCANADA CLINICAL-TRIALS GROUP-STUDY, Investigational new drugs, 16(1), 1998, pp. 51-56
RETROSPECTIVE COMPARATIVE-ANALYSIS OF 5FU PLUS LOW-DOSE FOLINIC ACID VS 5FU PLUS HIGH-DOSE FOLINIC ACID IN THE TREATMENT OF METASTATIC COLORECTAL-CANCER - THE OTTAWA EXPERIENCE
Authors: MAROUN JA CRIPPS C GOEL R DAHROUGE S BOISVERT D
Citation: Ja. Maroun et al., RETROSPECTIVE COMPARATIVE-ANALYSIS OF 5FU PLUS LOW-DOSE FOLINIC ACID VS 5FU PLUS HIGH-DOSE FOLINIC ACID IN THE TREATMENT OF METASTATIC COLORECTAL-CANCER - THE OTTAWA EXPERIENCE, American journal of clinical oncology, 20(4), 1997, pp. 387-392
ORAL ETOPOSIDE AND CARBOPLATIN - EFFECTIVE THERAPY FOR ELDERLY PATIENTS WITH SMALL-CELL LUNG-CANCER
Authors: EVANS WK RADWI A TOMIAK E LOGAN DM MARTINS H STEWART DJ GOSS G MAROUN JA DAHROUGE S
Citation: Wk. Evans et al., ORAL ETOPOSIDE AND CARBOPLATIN - EFFECTIVE THERAPY FOR ELDERLY PATIENTS WITH SMALL-CELL LUNG-CANCER, American journal of clinical oncology, 18(2), 1995, pp. 149-155
PHARMACOLOGY, RELATIVE BIOAVAILABILITY, AND TOXICITY OF 3 DIFFERENT ORAL CYCLOPHOSPHAMIDE PREPARATIONS IN A RANDOMIZED, CROSS-OVER STUDY
Authors: STEWART DJ MORGAN LR VERMA S MAROUN JA THIBAULT M
Citation: Dj. Stewart et al., PHARMACOLOGY, RELATIVE BIOAVAILABILITY, AND TOXICITY OF 3 DIFFERENT ORAL CYCLOPHOSPHAMIDE PREPARATIONS IN A RANDOMIZED, CROSS-OVER STUDY, Investigational new drugs, 13(1), 1995, pp. 99-107
VP-16, IFOSFAMIDE AND CISPLATIN (VIP) FOR EXTENSIVE SMALL-CELL LUNG-CANCER
Authors: EVANS WK STEWART DJ SHEPHERD FA LOGAN D GOSS G MAROUN JA WIERZBICKI R WARNER E LATREILLE J DAHROUGE S
Citation: Wk. Evans et al., VP-16, IFOSFAMIDE AND CISPLATIN (VIP) FOR EXTENSIVE SMALL-CELL LUNG-CANCER, European journal of cancer, 30A(3), 1994, pp. 299-303
PHASE-II STUDY ON DUP-937 (TELOXANTRONE) IN COLORECTAL-CARCINOMA - A CANADIAN-NATIONAL-CANCER-INSTITUTE CLINICAL-TRIAL GROUP-STUDY
Authors: MAROUN JA SKILLINGS J MACCORMICK R POTVIN M WIELGOSZ G DAVIDSON JR EISENHAUER E
Citation: Ja. Maroun et al., PHASE-II STUDY ON DUP-937 (TELOXANTRONE) IN COLORECTAL-CARCINOMA - A CANADIAN-NATIONAL-CANCER-INSTITUTE CLINICAL-TRIAL GROUP-STUDY, Investigational new drugs, 11(2-3), 1993, pp. 235-237
Risultati: 1-8 |